EUCTR2008-004874-42-DE
Active, not recruiting
Phase 1
Evaluation of predictive Factors for the Effectivity of Aromatase Inhibitor Therapy - Offene, prospektive, multizentrische Phase IV-Studie zur Untersuchung des Einflusses von pharmakogenetischen Markern auf die Wirksamkeit und Nebenwirkungsrate bei postmenopausalen, steroidhormonrezeptorpositiven Mammakarzinomspatientinnen, die mit Letrozol behandelt werden. - PreFace
DrugsFemara
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Institut für Frauengesundheit GmbH
- Enrollment
- 3500
- Status
- Active, not recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Indication for adjvuant antihormonal treatment of breast cancer
- •Age \= 18 years
- •Histological proven hormonal receptor positive breast cancer
- •No evidence of distant breast cancer disease
- •Patient must be postmenopausal
- •Postmenopausal is defined as one of the following criteria
- •Age above 55 years
- •Age \=55 years, but no spontaneous menstruation since 12 months
- •Age \=55 years and postmenopausal gonadotropin levels (luteinizing Hormone and follicle\-stimulating hormone \>40 IU/L)
- •Bilateral Oophorectomy
Exclusion Criteria
- •Patients who have no indication for an aromatase inhibitor or have a known hypersensitivity to letrozole
- •Prior treatment with letrozole other aromatase inhibitors
- •Evidence of distant metastastatic breast cancer disease
- •Unstable or serious co\-existing medical condition, including potentially serious infection that would make the patient inappropriate for study participation, or any serious medical or psychiatric disorder that would interfere with the patient’s safety or informed consent. (No specific tests are required for confirmation of egilibility)
- •Other concurrent malignant disease with the exception of cone\-biopsied in situ carcinoma of the cervix uteri, or adequately treated basal or squamous cell carcinoma of the skin, or other curable cancers e.g. Hodgkin’s disease or non\-Hodgkin\-lymphoma, provided 5 years have elapsed from completion of therapy, and there has been no recurrence
- •Patients with unstable angina, or uncontrolled cardiac disease (e.g. Class III and IV New York Heart Association’s Functional Classification) or uncontrolled endocrine disorders.
- •Instabiler Diabetes mellitus
- •Other antihormonal investigational or non\-investigational drugs within the past 30 days and the concomitant use of investigational or non\-investigational drugs except trastuzumab in the adjuvant treatment of HER2 positive breast cancer
- •Male patients
- •Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Evaluation of the predictive factors for the presence of small bowel ulcerative lesions and vascular lesions in patients with obscure gastrointestinal bleeding (OGIB): multicenter prospective studyobscure gastrointestinal bleeding (OGIB)JPRN-UMIN000008522Yokohama City University School of Medicine300
Completed
Not Applicable
Evaluation of the effects and predictive factors of double dose of adalimumab for the patients with Crohn's diseaseCrohn's diseaseJPRN-UMIN000022270Saitama Medical Center7
Completed
Not Applicable
The evaluation of the prediction factors for perioperative respiratory adverse effects in pediatric anesthesia for the dental proceduresJPRN-UMIN000024798Department of Dental Anesthesiology Kyushu University Faculty of Dental Science1,000
Recruiting
Not Applicable
The assessment for the predictive factor for the result of the oral food challenge testFood AllergyJPRN-UMIN000034608Gifu University1,000
Recruiting
Not Applicable
The study of predictive factors for the effect of Salmeterol/Fluticasone combination(SFC) on the patients with obstructive pulmonary dysfunction.obstructive pulmonary dysfunctionJPRN-UMIN000010276Kagoshima university pulmonary medicine60